BioInvent Q4 2024: January Readout an Anticlimax - Redeye

Redeye comments on BioInvent's fourth-quarter report 2024. The main event occurred in January 2025 with an anticipated important readout of BI-1808 monotherapy and BI-1206 triplet, which contained little new information on BI-1808 and just two patients for BI-1206, leading to a share price retreat. Nonetheless, BI-1808 and BI-1206 are on schedule for major readouts in mid-2025 with deal-making potential. We estimate a new base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1086178/bioinvent-q4-2024-january-readout-an-anticlimax?utm_source=finwire&utm_medium=RSS